Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation

Stock Information for VivoPower PLC

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VivoPower PLC

VivoPower Terminates $180 Million F-3 Registration Statement
Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply
Meridian Bioscience To Hold Second Quarter 2020 Financial Results Conference Call On May 8, 2020
Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests
MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH
Meridian Bioscience Announces FDA-Clearance for New Curian(TM) Analyzer and the Curian(TM) HpSA® Assay
Meridian's Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers
Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.